

Rapid and Robust Analysis Method for Quantifying Antidepressants and Major Metabolites in Human Serum by UHPLC-MS/MS

ASMS 2013 WP-095

Vincent Goudriaan¹, Christ Pijnenburg², Jacob Diepenbroek², Jan Giesbertsen², Annemieke Vermeulen Windsant-v.d. Tweel² ¹Shimadzu Benelux BV, 's-Hertogenbosch, Netherlands. ²ZANOB BV, 's-Hertogenbosch, Netherlands.

PO-CON1352E

1. Introduction

Therapeutic drug monitoring (TDM) of antidepressants is one of the most widely utilized analysis in clinical labs in Dutch hospitals nowadays. Traditionally quantitation of antidepressants is performed by means of HPLC with diode-array detection (DAD). Obvious disadvantages of the latter method are: sensitivity, selectivity and possibility of false positives as a result of co-elution with other administered drugs, metabolites or endogenic compounds. UHPLC-MS/MS is much more sensitive, more selective, and if robust the perfect replacement of routine HPLC analysis. Due to simplified sample prep, faster analysis and less solvent consumption UHPLC-MS/MS is much more cost effective. UHPLC-MS/MS methods will replace routine HPLC methods in clinical labs.

2. Methods and Materials

Human serum samples were extracted by means of off-line solid phase extraction. The extracts were analyzed with a Shimadzu Nexera UHPLC combined with a LCMS-8040 Tandem Mass Spectrometer. 5 µL of sample was injected with a SIL-30AC autosampler.

2-1. Sample Preparation

Standards both for calibration and control are ready made serum standards. The standards are pretreated in the same way as the samples.

Precondition SPE material1 with 1 mL 3% ammonia in acetonitrile
Equilibrate with 1 mL citrate buffer pH 3.0

 Load 2 mL internal standard solution
 Load 1 mL homogenized serum

Wash with 3 mL water (extract A0)
Wash with 3 mL acetonitrile (extract A1)
Wash with 3 mL 3% ammonia in acetonitrile (extract A2)
Bakerbond Speedisk C18 Polar Plus, 10 µm, 50 mg/3 mL (JT BAKER)

The flow is in all steps adjusted to about 1 to 2 mL/min.

Antidepressants in sample extract A2 are analyzed with UHPLC and a triple quadrupole mass spectrometer using the following conditions. Neutral and acidic compounds are eluted in extract A1.



High Speed Mass Spectrometer Ultra Fast Polarity Switching –15 msec Ultra Fast MRM –Min. dwell time 0.8 msec (max. 555 MRM/sec)

Fig. 1 LCMS-8040 Triple Quadrupole Mass Spectrometer

2-2. Analytical Conditions

UHPLC conditions (Nexera system)

Column	: Phenomenex Kinetex XB-C18 100 mm × 2.1 mm, 2.6 um	
Mobile phase A	: 10 mM Ammonium fomate	
В	: Acetonitrile	
Flow rate	: 0.4 mL/min	
Time program	: B conc.10%(0 min) -50%(2.5-5 min) - 75%(6 min) – 10% (7-7.5 min)	
Injection volume	: 5 μL	
Column temperature : 30°C		

MS conditions (LCMS-8040)

Ionization: ESI, PositiveScan mode: MRM mode with data dependent product ion scanning

Table 1 MRM transitions


Compound	Quantifier	Qualifiers
10-hydroxynortriptyline	280.20 > 215.10	280.20 > 262.20 ; 280.20 > 231.10
N-des methylclozapine	313.10 > 192.10	313.10 > 270.05 ; 313.10 > 231.05
clozapine	327.20 > 270.05	327.20 > 192.05 ; 327.20 > 227.05
paroxetine	330.20 > 70.20	330.20 > 192.20
fluvoxamine	319.20 > 71.15	319.20 > 41.15
desipramine	267.15 > 208.10	267.15 > 193.10 ; 267.15 > 236.10
imipramine	281.20 > 208.10	281.20 > 193.05
nortriptyline	264.20 > 233.20	264.20 > 91.15 ; 264.20 > 117.10
N-des methylfluoxetine	296.20 > 30.30	296.20 > 134.10
Amitriptyline	278.20 > 105.15	278.20 > 233.10 ; 278.20 > 91.10
Fluoxetine	310.15 > 44.25	310.15 > 148.10
N-des methylclomipramine	301.10 > 242.10	301.10 > 227.00 ; 301.10 > 270.10
Clomipramine	315.15 > 242.10	315.15 > 227.05 ; 315.15 > 270.10
internal standard	353.10 > 280.10	353.10 > 248.10 ; 353.10 > 308.05


3. Results

3-1. Comparison of HPLC-DAD and UHPLC-MS/MS results

Several hundreds of serum extracts were analyzed with a LC-MS/MS method and three separate HPLC methods with

photo diode-array detection to compare results of both techniques.








Fig. 3 Comparison of measured results with HPLC-DAD with UHPLC-MS/MS. N-desmethylclozapine shows signs of ion-suppression

3-2. Automatic Synchronized Survey Scanning (DDA)

The multi-component MRM method was extended with Synchronized Survey Events (DDA), to collect product ion scans for every positive peak above a certain level. The product ion spectra were identified by library search.




Fig. 4 N-desmethylclozapine (4A) and clozapine (4B) were both positively identified in the same patient serum extract

4. Conclusions

- There is a good correlation between the results from HPLC-DAD and UHPLC-MS/MS. Correlation coefficient is between 0.965 and 0.995 for all compounds. Only N-desmethyl-clozapine deviates due to ion-suppression. Generally can be concluded that the serum extracts obtained after off-line solid phase extraction are clean. There is no need for isotopically labeled internal standards.
- Combining MRM measurements with data dependent product ion scanning provides more reliable results since the identity of compounds can be confirmed by library search. Furthermore it is possible to combine diode-array detection with LCMS/MS to offer even more assurance.
- Co-medication and medication adherence behavior of elderly patients is more easily traced by multi-target compound analysis by UHPLC-MS/MS, as with HPLC-DAD one needs the trained eye of an analyst.
- Reconstitution of the sample extract by solvent evaporation and subsequent dilution in another solvent is mandatory for HPLC-DAD to increase concentration and to eliminate peak broadening of early eluting compounds, but is not necessary for UHPLC-MS/MS. Therefore sample pretreatment could be shortened, reducing the overall sample prep time from 40 to 15 minutes per batch of 15 samples.
- UHPLC-MS/MS method for antidepressants will replace routine HPLC-DAD methods in clinical labs.



First Edition: June, 2013



Shimadzu Corporation www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.